Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Equil patch insulin pump shows similar efficacy to Medtronic pump in T2DM management
Última actualización 12 de julio de 2026
Key finding
There was no significant difference in parameters of daily GV between the Equil patch insulin pump treatment and the Medtronic insulin pump treatment.
This study compared the Equil patch insulin pump and the Medtronic MMT-712 insulin pump in treating Type 2 diabetes, finding no significant differences in key outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the Equil patch insulin pump and the Medtronic MMT-712 insulin pump in treating Type 2 diabetes, finding no significant differences in key outcomes.
Clinical relevance
Understanding the comparative effectiveness of different insulin delivery systems is crucial for optimizing diabetes management. This study provides valuable insights for clinicians and patients in choosing between the Equil patch and Medtronic insulin pumps, suggesting that either option may be equally effective for glycemic control.
Keep in mind
The study may have limited generalizability due to the specific participant characteristics. Sample size and duration of the study may not capture long-term effects. Potential unmeasured confounders could influence the outcomes.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Yu‐Jiao L, Zi‐Yue S, Yun‐Qing Z, Da‐Shuang C, Jian Z. Comparison of the Equil Patch and Medtronic MMT-712 Insulin Pump Treatments in Type 2 Diabetes. Journal of Diabetes. 2024;16(4):e13536. doi:10.1111/1753-0407.13536
Efectos Principales
No significant difference in glycemic variability between the two insulin pump treatments.
No difference in time in range (TIR) observed between the Equil patch and Medtronic pumps.
No significant difference in the incidence of hypoglycemia between treatments.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin pump and Glucose variability, Hypoglycemia events, Postprandial blood glucose, and 3 more.
This study contributes evidence to
Primary intervention
Insulin pump
Primary outcomes
- Glucose variability
- Hypoglycemia events
- Postprandial blood glucose
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
6
Evidence pairs
480
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Insulin Delivery Systems and CGM Time in Range
Evidencia relacionada
Relación de evidencia
Insulin Delivery Systems and Hypoglycemia
Guardar evidencia
Relación de evidencia
Insulin Delivery Systems and Glucose Variability
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerPostprandial blood glucose
Insulin pump → Postprandial blood glucose
Insulin pump → Postprandial blood glucose
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Both treatments showed no significant difference in time below range (TBR).
- Postprandial glucose excursions were similar for both insulin pumps.
- The incidence of hypoglycemia was comparable between the two treatments.
A quién se aplica
- Adults diagnosed with Type 2 diabetes.
- Patients requiring insulin therapy for blood glucose management.
Tener en Cuenta
- Results may not apply to populations outside the study's demographic.
- The study's findings are based on short-term data; long-term effects remain unclear.
- Variability in individual responses to insulin therapy was not fully explored.
Entre Líneas
- The study may have limited generalizability due to the specific participant characteristics.
- Sample size and duration of the study may not capture long-term effects.
- Potential unmeasured confounders could influence the outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin Delivery Systems improve cgm time in range?
Strong Evidence
Insulin Delivery Systems may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Time above range
EvidenceScore™ Strong | EvidenceScore™ 88.2 | neutral | ConsistencyScore™ Unclear | 1 study
- 2
Time below range
EvidenceScore™ Strong | EvidenceScore™ 88.2 | neutral | ConsistencyScore™ Unclear | 1 study
- 3
Time in range
EvidenceScore™ Strong | EvidenceScore™ 88.2 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Insulin Delivery Systems affect hypoglycemia?
Strong Evidence
Current evidence does not show a clear benefit of Insulin Delivery Systems for Hypoglycemia.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Strong | EvidenceScore™ 83.8 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Does Insulin Delivery Systems improve glucose variability?
Strong Evidence
Current evidence does not show a clear benefit of Insulin Delivery Systems for Glucose Variability.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Glucose variability
EvidenceScore™ Strong | EvidenceScore™ 79.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 4 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Does Insulin Delivery Systems improve postprandial and ogtt glucose?
Limited Evidence
Current evidence does not show a clear benefit of Insulin Delivery Systems for Postprandial and OGTT Glucose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Postprandial blood glucose
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Acarbose may improve glycemic variability compared to sitagliptin.CGM enhances glycaemic control in chronic pancreatitis diabetes.Closed-loop therapy enhances glycemic control in type 2 diabetes.Cloud platform improves algorithm testing for type 1 diabetesInsulin pumps linked to higher preterm delivery in type 1 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.